103 related articles for article (PubMed ID: 31986004)
21. Radioactive gold nanoparticles in cancer therapy: therapeutic efficacy studies of GA-198AuNP nanoconstruct in prostate tumor-bearing mice.
Chanda N; Kan P; Watkinson LD; Shukla R; Zambre A; Carmack TL; Engelbrecht H; Lever JR; Katti K; Fent GM; Casteel SW; Smith CJ; Miller WH; Jurisson S; Boote E; Robertson JD; Cutler C; Dobrovolskaia M; Kannan R; Katti KV
Nanomedicine; 2010 Apr; 6(2):201-9. PubMed ID: 19914401
[TBL] [Abstract][Full Text] [Related]
22. Nanocarriers for microRNA delivery in cancer medicine.
Fernandez-Piñeiro I; Badiola I; Sanchez A
Biotechnol Adv; 2017; 35(3):350-360. PubMed ID: 28286148
[TBL] [Abstract][Full Text] [Related]
23. Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo.
Yan J; Wang Y; Zhang X; Liu S; Tian C; Wang H
Drug Deliv; 2016 Jun; 23(5):1757-62. PubMed ID: 26203689
[TBL] [Abstract][Full Text] [Related]
24. miR-221-5p regulates proliferation and migration in human prostate cancer cells and reduces tumor growth in vivo.
Kiener M; Chen L; Krebs M; Grosjean J; Klima I; Kalogirou C; Riedmiller H; Kneitz B; Thalmann GN; Snaar-Jagalska E; Spahn M; Kruithof-de Julio M; Zoni E
BMC Cancer; 2019 Jun; 19(1):627. PubMed ID: 31238903
[TBL] [Abstract][Full Text] [Related]
25. Optical imaging and anticancer chemotherapy through carbon dot created hollow mesoporous silica nanoparticles.
Kang MS; Singh RK; Kim TH; Kim JH; Patel KD; Kim HW
Acta Biomater; 2017 Jun; 55():466-480. PubMed ID: 28373086
[TBL] [Abstract][Full Text] [Related]
26. Cytosolic co-delivery of miRNA-34a and docetaxel with core-shell nanocarriers via caveolae-mediated pathway for the treatment of metastatic breast cancer.
Zhang L; Yang X; Lv Y; Xin X; Qin C; Han X; Yang L; He W; Yin L
Sci Rep; 2017 Apr; 7():46186. PubMed ID: 28383524
[TBL] [Abstract][Full Text] [Related]
27. Tumor-Acidity-Cleavable Maleic Acid Amide (TACMAA): A Powerful Tool for Designing Smart Nanoparticles To Overcome Delivery Barriers in Cancer Nanomedicine.
Du JZ; Li HJ; Wang J
Acc Chem Res; 2018 Nov; 51(11):2848-2856. PubMed ID: 30346728
[TBL] [Abstract][Full Text] [Related]
28. L-securinine inhibits cell growth and metastasis of human androgen-independent prostate cancer DU145 cells via regulating mitochondrial and AGTR1/MEK/ERK/STAT3/PAX2 apoptotic pathways.
Zhang D; Liu H; Yang B; Hu J; Cheng Y
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30975734
[TBL] [Abstract][Full Text] [Related]
29. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
30. Signaling mechanisms that mediate invasion in prostate cancer cells.
Bonaccorsi L; Marchiani S; Muratori M; Carloni V; Forti G; Baldi E
Ann N Y Acad Sci; 2004 Dec; 1028():283-8. PubMed ID: 15650253
[TBL] [Abstract][Full Text] [Related]
31. Etoposide encased folic acid adorned mesoporous silica nanoparticles as potent nanovehicles for enhanced prostate cancer therapy: synthesis, characterization, cellular uptake and biodistribution.
Saroj S; Rajput SJ
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S1115-S1130. PubMed ID: 30669865
[TBL] [Abstract][Full Text] [Related]
32. [Screening of membrane antigen differentially expressed in androgen-dependent prostate cancer and androgen-independent prostate cancer].
Zhang X; Tang Z; Qi L; Chen H; Luo Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Aug; 37(8):817-23. PubMed ID: 22954909
[TBL] [Abstract][Full Text] [Related]
33. Cooperative dual-activity targeted nanomedicine for specific and effective prostate cancer therapy.
Yang HW; Hua MY; Liu HL; Tsai RY; Chuang CK; Chu PC; Wu PY; Chang YH; Chuang HC; Yu KJ; Pang ST
ACS Nano; 2012 Feb; 6(2):1795-805. PubMed ID: 22248493
[TBL] [Abstract][Full Text] [Related]
34. CX3CL1 increases invasiveness and metastasis by promoting epithelial-to-mesenchymal transition through the TACE/TGF-α/EGFR pathway in hypoxic androgen-independent prostate cancer cells.
Tang J; Xiao L; Cui R; Li D; Zheng X; Zhu L; Sun H; Pan Y; Du Y; Yu X
Oncol Rep; 2016 Feb; 35(2):1153-62. PubMed ID: 26718770
[TBL] [Abstract][Full Text] [Related]
35. [Current opinions on the treatment of androgen-independent prostate cancer].
Guan XX; Chen LB
Zhonghua Nan Ke Xue; 2006 Nov; 12(11):1021-5. PubMed ID: 17146932
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome.
Huang M; Narita S; Tsuchiya N; Ma Z; Numakura K; Obara T; Tsuruta H; Saito M; Inoue T; Horikawa Y; Satoh S; Habuchi T
Carcinogenesis; 2011 Nov; 32(11):1589-96. PubMed ID: 21828059
[TBL] [Abstract][Full Text] [Related]
37. The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer.
Fizazi K; Martinez LA; Sikes CR; Johnston DA; Stephens LC; McDonnell TJ; Logothetis CJ; Trapman J; Pisters LL; Ordoñez NG; Troncoso P; Navone NM
Clin Cancer Res; 2002 Mar; 8(3):775-81. PubMed ID: 11895908
[TBL] [Abstract][Full Text] [Related]
38. Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer.
Svatek R; Karakiewicz PI; Shulman M; Karam J; Perrotte P; Benaim E
Eur Urol; 2006 Apr; 49(4):666-74. PubMed ID: 16423446
[TBL] [Abstract][Full Text] [Related]
39. hsa-miR-135a-1 inhibits prostate cancer cell growth and migration by targeting EGFR.
Xu B; Tao T; Wang Y; Fang F; Huang Y; Chen S; Zhu W; Chen M
Tumour Biol; 2016 Oct; 37(10):14141-14151. PubMed ID: 27524492
[TBL] [Abstract][Full Text] [Related]
40. Hybrid nanocarrier system for guiding and augmenting simvastatin cytotoxic activity against prostate cancer.
Sedki M; Khalil IA; El-Sherbiny IM
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S641-S650. PubMed ID: 30295086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
